A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...
A groundbreaking Australian clinical trial has shown that a majority of melanoma patients whose cancer has spread to the ...
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...
Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...
Medpage Today on MSN2d
More Progress for Bladder-Sparing Strategies in Muscle-Invasive CancerNeoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...
(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback